Miquel Vila Bover

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

Instituciones de las que forman parte

Jefe de grupo
Enfermedades Neurodegenerativas

Vall Hebron Institut de Recerca

Miquel Vila Bover

Instituciones de las que forman parte

Jefe de grupo
Enfermedades Neurodegenerativas

Vall Hebron Institut de Recerca

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

I have a degree in Medicine and Surgery from the University of Barcelona (1993) and a PhD in Neuroscience from the University of Paris 6 (1998). My doctoral work carried out in the laboratory of experimental neurology at the Salpetriere Hospital in Paris (1993-98) contributed to establishing the subthalamic nucleus as the main therapeutic target for the surgical treatment of Parkinson's disease with deep brain stimulation. From 1998 to 2005 I worked at the Movement Disorders Unit of Columbia University in New York (USA), initially as a postdoctoral researcher and from 2001 as an Assistant Professor of Neurology, focusing on the study of the mechanisms of neuronal death in Parkinson's disease to identify new therapeutic targets for this currently incurable neurodegenerative disorder.

In 2006 I moved to Barcelona as a Professor at ICREA (Catalan Institute of Research and Advanced Studies) to create and lead a new research group in neurodegenerative diseases at the Vall d'Hebron Research Institute (VHIR). Our group is now part of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) and the Aligning Science Across Parkinson's Collaborative Research Network (ASAP-CRN).

I am also an Associate Professor at the Autonomous University of Barcelona, Principal Investigator at CIBERNED, Coordinating Lead PI at ASAP-CRN and member of the Steering Committees of the World Parkinson Coalition and the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society.

Proyectos

Rol de la neuromelanina en la enfermedad de Parkinson y del envejecimiento cerebral: estudio `ptemcoañ terpéutico en nuevos modelos preclínicos "humanizados" in vivo.

IP: Miquel Vila Bover
Colaboradores: Ariadna Laguna Tuset
Entidad financiadora: Ministerio Economía, Industria y Competitividad
Financiación: 363000
Referencia: SAF2016-77541-R
Duración: 30/12/2016 - 29/12/2020

Sol·licitud Miguel Servet II

IP: Miquel Vila Bover
Colaboradores: Jordi Bove Badell, Laia Perez Lasarte
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 91125
Referencia: CPII16/00029
Duración: 01/01/2017 - 31/12/2019

Targeting a novel transcriptional pathway to reduce á-synuclein expression

IP: Miquel Vila Bover
Colaboradores: -
Entidad financiadora: Michael J. Fox Foundation
Financiación: 31728
Referencia: TARGET,ADV_MJFF2016 M.VILA
Duración: 21/12/2016 - 20/06/2018

Estudio del rol patogénico de la disfunción autofágica en la enfermedad de Parkinson asociada a mutaciones en GBA. Desarrollo de nuevos fármacos moduladores de la autofagia como nueva estrategia terapéutica en las enfermedades neurodegenerativas.

IP: Miquel Vila Bover
Colaboradores: Marta Martínez Vicente, Laia Perez Lasarte
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 101250
Referencia: CPII15/00007
Duración: 01/01/2016 - 31/12/2018